Hajdu D, Aiglová K, Vinklerová I, Urbánek K
Department of Pharmacology, Faculty of Medicine and Dentistry of Palacky University and University Hospital, Olomouc, Czech Republic.
J Clin Pharm Ther. 2009 Oct;34(5):599-602. doi: 10.1111/j.1365-2710.2009.01029.x.
We report a case of acute liver injury probably due to fenofibrate. A 50-year-old female without a history of liver disease developed cholestatic hepatitis during her second week of fenofibrate treatment. Laboratory tests on admission showed serum bilirubin 534.0 mcmol/L (conjugated 444.0), alkaline phosphatase (AP) 8.76, gamma-glutamyl traspeptidase (GGT) 20.92, alanine aminotransferase (ALT) 2.6, aspartate aminotransferase (AST) 3.64 mckat/L. Fenofibrate withdrawal and ursodeoxycholic acid (750 mg daily) administration was rapidly followed by a favourable outcome.
我们报告一例可能由非诺贝特引起的急性肝损伤病例。一名无肝脏疾病史的50岁女性在接受非诺贝特治疗的第二周出现胆汁淤积性肝炎。入院时实验室检查显示血清胆红素534.0微摩尔/升(结合胆红素444.0)、碱性磷酸酶(AP)8.76、γ-谷氨酰转肽酶(GGT)20.92、丙氨酸转氨酶(ALT)2.6、天冬氨酸转氨酶(AST)3.64微卡特/升。停用非诺贝特并给予熊去氧胆酸(每日750毫克)后,病情迅速好转。